Hims & Hers announces Wegovy pill copy; Novo Nordisk vows legal action
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
A restless leg syndrome drug led me to compulsive gambling
I was a tenured professor, a published novelist, and a married father of two sons when I lost…
Pfizer’s monthly obesity injection drove shows promise in trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it…
Eli Lilly CEO David Ricks talks Medicare coverage of obesity pills
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major…
Eli Lilly plans $3.5 billion Pennsylvania plant for obesity drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Sept. 23, 2025. Antranik…
UnitedHealth Group (UNH) earnings Q4 2025
UnitedHealth Group Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US,…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Japan to designate eight ingredients for list of drugs with abuse risk
The health ministry will designate eight drug ingredients as having abuse potential under the law in response to…
Next steps for Eli Lilly, Novo Nordisk, Pfizer
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George…
Number of new U.S. drug shortages hits lowest level in 20 years
The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…